Format

Send to

Choose Destination
See comment in PubMed Commons below
Indian J Psychiatry. 2005 Apr;47(2):84-8. doi: 10.4103/0019-5545.55951.

Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients.

Author information

  • 1Additional Professor of Psychiatry, Postgraduate Institute of Medical Education and Research.

Abstract

BACKGROUND:

Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India.

AIM:

To compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressive disorder.

METHODS:

In this prospective study, patients (n=60) were randomly assigned to treatment with moclobemide or imipramine for 6 weeks. Efficacy of the drugs was assessed by observing the mean change in scores on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Scale (MADRS).

RESULTS:

Both the groups showed significant decrease in scores at the end of 6 weeks. Patients who received moclobemide had a better side-effect profile.

CONCLUSION:

Moclobemide is an effective antidepressant and is better tolerated than imipramine.

KEYWORDS:

Moclobemide; depression; monoamine oxidase-A inhibitor

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk